$155.68
-3.37[-2.12%]
At close: Apr 25
$155.68
0[0.00%]
After Hours: 4:20PM EDT
Krystal Biotech
(NASDAQ:KRYS)Krystal Biotech Stock (NASDAQ:KRYS), Analyst Ratings, Price Targets, Predictions
Krystal Biotech Inc has a consensus price target of $170.55, established from looking at the 43 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., Stifel, and Citigroup on April 22, 2024, April 16, 2024, and February 27, 2024. With an average price target of $199.67 between HC Wainwright & Co., Stifel, and Citigroup, there's an implied 28.25% upside for Krystal Biotech Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Stifel
Citigroup
Guggenheim
Cantor Fitzgerald
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Krystal Biotech
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/22/2024 | KRYS | Buy Now | Krystal Biotech | $155.68 | 28.47% | HC Wainwright & Co. | Joseph Pantginis | → $200 | Reiterates | Buy → Buy | Get Alert |
| 04/16/2024 | KRYS | Buy Now | Krystal Biotech | $155.68 | 31.04% | Stifel | Dae Gon Ha | $178 → $204 | Reiterates | Buy → Buy | Get Alert |
| 02/27/2024 | KRYS | Buy Now | Krystal Biotech | $155.68 | 25.26% | Citigroup | Yigal Nochomovitz | $160 → $195 | Maintains | Buy | Get Alert |
| 02/27/2024 | KRYS | Buy Now | Krystal Biotech | $155.68 | 12.41% | Guggenheim | Debjit Chattopadhyay | $130 → $175 | Maintains | Buy | Get Alert |
| 12/13/2023 | KRYS | Buy Now | Krystal Biotech | $155.68 | 15.62% | Cantor Fitzgerald | Josh Schimmer | $160 → $180 | Maintains | Overweight | Get Alert |
| 11/20/2023 | KRYS | Buy Now | Krystal Biotech | $155.68 | 2.77% | Goldman Sachs | Andrea Tan | → $160 | Initiates | → Buy | Get Alert |
| 11/07/2023 | KRYS | Buy Now | Krystal Biotech | $155.68 | 2.77% | Cantor Fitzgerald | Josh Schimmer | → $160 | Reiterates | Overweight → Overweight | Get Alert |
| 10/24/2023 | KRYS | Buy Now | Krystal Biotech | $155.68 | 2.77% | Cantor Fitzgerald | Josh Schimmer | → $160 | Initiates | → Overweight | Get Alert |
| 10/12/2023 | KRYS | Buy Now | Krystal Biotech | $155.68 | 2.77% | Citigroup | Carly Kenselaar | → $160 | Initiates | → Buy | Get Alert |
| 09/07/2023 | KRYS | Buy Now | Krystal Biotech | $155.68 | -1.08% | Berenberg | Caroline Palomeque | → $154 | Initiates | → Buy | Get Alert |
| 08/08/2023 | KRYS | Buy Now | Krystal Biotech | $155.68 | -1.72% | Chardan Capital | Geulah Livshits | $148 → $153 | Maintains | Buy | Get Alert |
| 08/07/2023 | KRYS | Buy Now | Krystal Biotech | $155.68 | -10.71% | HC Wainwright & Co. | Joseph Pantginis | → $139 | Reiterates | Buy → Buy | Get Alert |
| 07/27/2023 | KRYS | Buy Now | Krystal Biotech | $155.68 | -10.71% | HC Wainwright & Co. | Joseph Pantginis | → $139 | Reiterates | Buy → Buy | Get Alert |
| 07/03/2023 | KRYS | Buy Now | Krystal Biotech | $155.68 | -10.71% | HC Wainwright & Co. | Joseph Pantginis | → $139 | Reiterates | → Buy | Get Alert |
| 05/25/2023 | KRYS | Buy Now | Krystal Biotech | $155.68 | -10.07% | B of A Securities | Alec Stranahan | $118 → $140 | Maintains | Buy | Get Alert |
| 05/24/2023 | KRYS | Buy Now | Krystal Biotech | $155.68 | -6.86% | Stifel | Dae Gon Ha | $102 → $145 | Maintains | Buy | Get Alert |
| 05/22/2023 | KRYS | Buy Now | Krystal Biotech | $155.68 | -16.5% | Guggenheim | Debjit Chattopadhyay | $101 → $130 | Maintains | Buy | Get Alert |
| 05/22/2023 | KRYS | Buy Now | Krystal Biotech | $155.68 | -0.44% | Goldman Sachs | Madhu Kumar | $135 → $155 | Maintains | Buy | Get Alert |
| 05/22/2023 | KRYS | Buy Now | Krystal Biotech | $155.68 | -4.93% | Chardan Capital | Geulah Livshits | $133 → $148 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Krystal Biotech (KRYS)?
The latest price target for Krystal Biotech (NASDAQ: KRYS) was reported by HC Wainwright & Co. on April 22, 2024. The analyst firm set a price target for $200.00 expecting KRYS to rise to within 12 months (a possible 28.47% upside). 22 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Krystal Biotech (KRYS)?
The latest analyst rating for Krystal Biotech (NASDAQ: KRYS) was provided by HC Wainwright & Co., and Krystal Biotech reiterated their buy rating.
When was the last upgrade for Krystal Biotech (KRYS)?
The last upgrade for Krystal Biotech Inc happened on February 28, 2023 when Goldman Sachs raised their price target to $124. Goldman Sachs previously had a neutral for Krystal Biotech Inc.
When was the last downgrade for Krystal Biotech (KRYS)?
The last downgrade for Krystal Biotech Inc happened on August 25, 2022 when Goldman Sachs changed their price target from N/A to $74 for Krystal Biotech Inc.
When is the next analyst rating going to be posted or updated for Krystal Biotech (KRYS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Krystal Biotech, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Krystal Biotech was filed on April 22, 2024 so you should expect the next rating to be made available sometime around April 22, 2025.
Is the Analyst Rating Krystal Biotech (KRYS) correct?
While ratings are subjective and will change, the latest Krystal Biotech (KRYS) rating was a reiterated with a price target of $0.00 to $200.00. The current price Krystal Biotech (KRYS) is trading at is $155.68, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.